Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 33

1.

Plasma lncRNA expression profile as a prognostic tool in BRAF-mutant metastatic melanoma patients treated with BRAF inhibitor.

Kolenda T, Rutkowski P, Michalak M, Kozak K, Guglas K, Ryś M, Galus Ł, Woźniak S, Ługowska I, Gos A, Teresiak A, Mackiewicz A, Lamperska K, Mackiewicz J.

Oncotarget. 2019 Jun 11;10(39):3879-3893. doi: 10.18632/oncotarget.26989. eCollection 2019 Jun 11.

2.

Oncogenic Role of ZFAS1 lncRNA in Head and Neck Squamous Cell Carcinomas.

Kolenda T, Guglas K, Kopczyńska M, Teresiak A, Bliźniak R, Mackiewicz A, Lamperska K, Mackiewicz J.

Cells. 2019 Apr 21;8(4). pii: E366. doi: 10.3390/cells8040366.

3.

EGOT lncRNA in head and neck squamous cell carcinomas.

Kolenda T, Kopczyńska M, Guglas K, Teresiak A, Bliźniak R, Łasińska I, Mackiewicz J, Lamperska K.

Pol J Pathol. 2018;69(4):356-365. doi: 10.5114/pjp.2018.81695.

4.
5.

Integrins as A New Target for Cancer Treatment.

Łasiñska I, Mackiewicz J.

Anticancer Agents Med Chem. 2018 Nov 18. doi: 10.2174/1871520618666181119103413. [Epub ahead of print]

PMID:
30451118
6.

lncRNA Expression after Irradiation and Chemoexposure of HNSCC Cell Lines.

Guglas K, Kolenda T, Teresiak A, Kopczyńska M, Łasińska I, Mackiewicz J, Mackiewicz A, Lamperska K.

Noncoding RNA. 2018 Nov 14;4(4). pii: E33. doi: 10.3390/ncrna4040033.

7.

Whole cell melanoma vaccine genetically modified to stem cells like phenotype generates specific immune responses to ALDH1A1 and long-term survival in advanced melanoma patients.

Kwiatkowska-Borowczyk E, Czerwińska P, Mackiewicz J, Gryska K, Kazimierczak U, Tomela K, Przybyła A, Kozłowska AK, Galus Ł, Kwinta Ł, Dondajewska E, Gąbka-Buszek A, Żakowska M, Mackiewicz A.

Oncoimmunology. 2018 Aug 24;7(11):e1509821. doi: 10.1080/2162402X.2018.1509821. eCollection 2018.

8.

Immunotherapy in Patients with Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck.

Lasinska I, Kolenda T, Teresiak A, Lamperska KM, Galus L, Mackiewicz J.

Anticancer Agents Med Chem. 2018 Sep 9. doi: 10.2174/1871520618666180910092356. [Epub ahead of print]

PMID:
30198439
9.

High baseline neutrophil-to-lymphocyte ratio predicts worse outcome in patients with metastatic BRAF-positive melanoma treated with BRAF and MEK inhibitors.

Teterycz P, Jagodzińska-Mucha P, Cybulska-Stopa B, Mariuk-Jarema A, Kozak K, Koseła-Paterczyk H, Czarnecka AM, Rajczykowski M, Dziura R, Galus Ł, Mackiewicz J, Świtaj T, Klimczak A, Falkowski S, Suwiński R, Ziobro M, Ługowska I, Rutkowski P.

Melanoma Res. 2018 Oct;28(5):435-441. doi: 10.1097/CMR.0000000000000461.

PMID:
29782381
10.

BRAF and MEK inhibitors in the era of immunotherapy in melanoma patients.

Mackiewicz J, Mackiewicz A.

Contemp Oncol (Pozn). 2018 Mar;22(1A):68-72. doi: 10.5114/wo.2018.73890. Epub 2018 Mar 5. Review.

11.

lncRNA in HNSCC: challenges and potential.

Guglas K, Bogaczyńska M, Kolenda T, Ryś M, Teresiak A, Bliźniak R, Łasińska I, Mackiewicz J, Lamperska K.

Contemp Oncol (Pozn). 2017;21(4):259-266. doi: 10.5114/wo.2017.72382. Epub 2017 Dec 30. Review.

12.

The comparison of acute toxicity in 2 treatment courses: Three-weekly and weekly cisplatin treatment administered with radiotherapy in patients with head and neck squamous cell carcinoma.

Mackiewicz J, Rybarczyk-Kasiuchnicz A, Łasińska I, Mazur-Roszak M, Świniuch D, Michalak M, Kaźmierska J, Studniarek A, Krokowicz Ł, Bajon T.

Medicine (Baltimore). 2017 Dec;96(51):e9151. doi: 10.1097/MD.0000000000009151.

13.

Biological role of long non-coding RNA in head and neck cancers.

Kolenda T, Guglas K, Ryś M, Bogaczyńska M, Teresiak A, Bliźniak R, Łasińska I, Mackiewicz J, Lamperska KM.

Rep Pract Oncol Radiother. 2017 Sep-Oct;22(5):378-388. doi: 10.1016/j.rpor.2017.07.001. Epub 2017 Aug 1. Review.

14.

Programmed cell death 1 checkpoint inhibitors in the treatment of patients with advanced melanoma.

Mackiewicz J, Mackiewicz A.

Contemp Oncol (Pozn). 2017;21(1):1-5. doi: 10.5114/wo.2017.66651. Epub 2017 Mar 22. Review.

15.

The outcomes of Polish patients with advanced BRAF-positive melanoma treated with vemurafenib in a safety clinical trial.

Rutkowski P, Kozak K, Mackiewicz J, Krzemieniecki K, Nawrocki S, Wasilewska-Teśluk E, Kwinta Ł, Wysocki P, Koseła-Paterczyk H, Świtaj T.

Contemp Oncol (Pozn). 2015;19(4):280-3. doi: 10.5114/wo.2015.54082. Epub 2015 Sep 28.

16.

Cell-based Hyper-interleukin 6 or Hyper-interleukin 11 secreting vaccines combined with low dose cyclophosphamide in an orthotopic murine prostate cancer model.

Mackiewicz J, Kotlarski M, Dondajewska E, Nowicka-Kotlarska A, Krokowicz Ł, Kazimierczak U.

Contemp Oncol (Pozn). 2015;19(3):187-94. doi: 10.5114/wo.2015.52711. Epub 2015 Jul 8.

17.

In Vitro Studies of Antibacterial and Antifungal Wound Dressings Comprising H2TiO3 and SiO2 Nanoparticles.

Krokowicz L, Tomczak H, Bobkiewicz A, Mackiewicz J, Marciniak R, Drews M, Banasiewicz T.

Pol J Microbiol. 2015;64(2):137-42.

18.

Cellular Vaccines Modified with Hyper IL6 or Hyper IL11 Combined with Docetaxel in an Orthotopic Prostate Cancer Model.

Mackiewicz J, Kazimierczak U, Kotlarski M, Dondajewska E, Kozłowska A, Kwiatkowska E, Nowicka-Kotlarska A, Dams-Kozłowska H, Wysocki PJ, Mackiewicz A.

Anticancer Res. 2015 Jun;35(6):3275-88.

PMID:
26026087
19.

Whole Cell Therapeutic Vaccine Modified With Hyper-IL6 for Combinational Treatment of Nonresected Advanced Melanoma.

Mackiewicz J, Karczewska-Dzionk A, Laciak M, Kapcinska M, Wiznerowicz M, Burzykowski T, Zakowska M, Rose-John S, Mackiewicz A.

Medicine (Baltimore). 2015 May;94(21):e853. doi: 10.1097/MD.0000000000000853. Erratum in: Medicine (Baltimore). 2015 Jun;94(25):1.

20.

Febrile neutropenia in a metastatic melanoma patient treated with ipilimumab - case report.

Woźniak S, Mackiewicz-Wysocka M, Krokowicz Ł, Kwinta Ł, Mackiewicz J.

Oncol Res Treat. 2015;38(3):105-8. doi: 10.1159/000377650. Epub 2015 Feb 20.

PMID:
25792081

Supplemental Content

Loading ...
Support Center